CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program
DOI 10.1055/s-0032-1332186
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, S Zeuzem, W Iraqi, A Hill, JM Läuffer, I Lonjon-Domanec, M Colombo
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir, pegylated interferon-alpha and ribavirin (PR) for 12 weeks, followed by PR. Liver biopsy or non-invasive tests showing severe fibrosis (Metavir F3 or Ishak 3–4) or cirrhosis (…
Zitieren
Zitierempfehlung
H Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, S Zeuzem, W Iraqi, A Hill, JM Läuffer, I Lonjon-Domanec, M Colombo (2013) Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0032-1332186
Mit CareLit weiterarbeiten